VFY — Vitrafy Life Sciences Cashflow Statement
0.000.00%
- AU$90.03m
- AU$113.36m
- AU$0.04m
Annual cashflow statement for Vitrafy Life Sciences, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Changes in Working Capital | 0.457 | 0.628 | 1.83 | 2.05 |
Other Operating Cash Flow | ||||
Cash from Operating Activities | -1.72 | -5.87 | -4.96 | -6.79 |
Capital Expenditures | -0.099 | -0.486 | -0.09 | -0.013 |
Purchase of Fixed Assets | ||||
Cash from Investing Activities | -0.099 | -0.486 | -0.09 | -0.013 |
Financing Cash Flow Items | -0.454 | 0 | -0.103 | -0.639 |
Other Financing Cash Flow | ||||
Net Issuance / Retirement of Stock | ||||
Net Issuance / Retirement of Debt | ||||
Cash from Financing Activities | 8.91 | -0.058 | 5.8 | 11.5 |
Beginning Cash Balance | ||||
Ending Cash Balance | ||||
Net Change in Cash | 7.09 | -6.42 | 0.758 | 4.69 |